These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25618750)

  • 1. Prophylactic vitamin D supplementation in ovarian hyperstimulation syndrome: an animal study.
    Turan GA; Eskicioglu F; Sivrikoz ON; Cengiz H; Gur EB; Tatar S; Sahin N; Yilmaz O
    Arch Gynecol Obstet; 2015 Aug; 292(2):421-7. PubMed ID: 25618750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
    Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
    Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
    Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.
    Chuderland D; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Ron-El R; Shalgi R
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E258-66. PubMed ID: 23295464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS).
    Birinci H; Vatansever HS; Yüncü M
    Reprod Fertil Dev; 2021 Nov; 33(16):799-809. PubMed ID: 34610858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study.
    Turan GA; Eskicioglu F; Sivrikoz ON; Cengiz H; Adakan S; Gur EB; Tatar S; Sahin N; Yilmaz O
    Arch Gynecol Obstet; 2015 Nov; 292(5):1163-71. PubMed ID: 25990477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dual Role of PEDF in the Pathogenesis of OHSS: Negating Both Angiogenic and Inflammatory Pathways.
    Miller I; Chuderland D; Grossman H; Ron-El R; Ben-Ami I; Shalgi R
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4699-4709. PubMed ID: 27680872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
    Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M
    Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.
    Pala Ş; Atilgan R; Ozkan ZS; Kavak SB; Ilhan N; Akpolat N; Sapmaz E
    Drug Des Devel Ther; 2015; 9():1761-6. PubMed ID: 25848212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
    Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
    Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The VEGF and PEDF levels in the follicular fluid of patients co- treated with LETROZOLE and gonadotropins during the stimulation cycle.
    Haas J; Bassil R; Gonen N; Meriano J; Jurisicova A; Casper RF
    Reprod Biol Endocrinol; 2018 May; 16(1):54. PubMed ID: 29843716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
    Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-dependent expression of PEDF and VEGF in blood serum and retina of rats with oxygen-induced retinopathy.
    Lei CT; Wu XL; Peng J; Chen XF; Qiao LF; Fan YC; Hu JB
    J Huazhong Univ Sci Technolog Med Sci; 2015 Feb; 35(1):135-139. PubMed ID: 25673207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
    van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
    Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A physiological approach for treating endometriosis by recombinant pigment epithelium-derived factor (PEDF).
    Chuderland D; Hasky N; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Shalgi R
    Hum Reprod; 2013 Jun; 28(6):1626-34. PubMed ID: 23466670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
    Gómez R; Lima I; Simón C; Pellicer A
    Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
    Eskicioğlu F; Turan GA; Sivrikoz ON; Cengiz H; Zafer A; Akan Z; Sahin N; Yilmaz O; Yeşil H; Vatansever S
    Ginekol Pol; 2015 Aug; 86(8):566-73. PubMed ID: 26492704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.